Combination of Selective PARP3 and PARP16 Inhibitory Analogues of Latonduine A Corrects F508del-CFTR Trafficking
Ryan M. Centko, Graeme W. Carlile, Isabel Barne, Brian O. Patrick, Polina D. Blagojević, David Y. Thomas, Raymond J. Andersen
Abstract
corrector activity in combination with the clinically approved corrector VX809, making it a potential new partner for cystic fibrosis combination drug therapies.
Topics & Concepts
ChemistryIn vitroIC50PotencyCystic fibrosis transmembrane conductance regulatorStereochemistryRegulatorMechanism of actionPharmacologyBiochemistryBiologyGeneCystic Fibrosis Research AdvancesAdvanced biosensing and bioanalysis techniquesBacterial biofilms and quorum sensing